Figure 1
From: Engineered CHO cells as a novel AAV production platform for gene therapy delivery
Plasmids constructs used for stable transfection and generation of stable pools. (a) Four individual cassettes: Pool 1 (CMV-HVEM) expressing HVEM; Pool 2 (CMV-HVEM-CO) expressing codon-optimized HVEM; Pool 3 (CMV-Nectin-1) expressing Nectin-1; and Pool 4 (CMV-Nectin-1-CO) expressing codon-optimized Nectin-1. The CMV promoter drives expression of all cassettes. (b) Four dual cassettes: Pool 5 (CMV-HVEM-Nectin-1) expressing both HVEM and Nectin-1; Pool 6 (CMV-HVEM-Nectin-1-CO) expressing codon-optimized HVEM and Nectin-1; Pool 7 (Spro-HVEM-Nectin-1) expressing HVEM and Nectin-1; and Pool 8 (Spro-HV-NE-CO) expressing codon-optimized HVEM and Nectin-1. The CMV promoter drives expression of gene cassettes in pools 5 and 6 while synthetic (Spro) promoter drives expression of gene cassettes in pool 7 and 8. (c) Percentage of HVEM expressing cells from pools: 1, 2, 5, 6, 7 and 8. (d) Percentage of Nectin-1 expressing cells from pools: 3, 4, 5, 6, 7 and 8. Figures (a) and (b) were created with BioRender.com.
